Table 3.
Prevalence of MDR among diarrhoeal E. coli pathotypes.
| ECD n (%) |
Phylogenic Group n (%) |
CIP n (%) |
KAN n (%) |
NAL n (%) |
NET n (%) |
SXT n (%) |
TET n (%) |
MDR n (%) |
ESβL Gene |
|---|---|---|---|---|---|---|---|---|---|
| EAEC | B2 | ||||||||
| 1 (4) | 1 (4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | blaCTX-M-15 |
| EIEC | D | 0 | 0 | 0 | 0 | 1 (5) | 1 (5) | 1 (4) | blaCTX-M-15 |
| 1 (4) | 1 (4) | ||||||||
| EHEC | D3 (12) | 3 (15) | 3 (15) | 2 (10) | 1 (5) | 1 (5) | 2 (10) | 3 (12) | blaCTX-M-15 |
| 3 (11.5) | |||||||||
| Atypical EPEC | E1(4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 1 (4) | |||||||||
| Typical EPEC | D1 (4) | 1 (5) | 1 (5) | 1 (5) | 0 | 0 | 0 | 1 (4) | blaCTX-M-15 |
| 2 (8) | |||||||||
| Total 8 (31) | 5 (20) |
GEN = gentamicin, TOB = tobramycin, NET = netilmicin, TET = tetracycline, STX = trimethoprim/sulfonamide, NAL = nalidixic acid, CIP = ciprofloxacin, FOS = fosfomycin, KAN = kanamycin, MDR = Multi-Drug Resistance.